Ethambutol PCD Pharma Franchise Company
Cafoli Lifecare is a trusted Ethambutol PCD pharma franchise company in India, offering a focused range of 4 Ethambutol formulations manufactured at WHO-GMP certified facilities. We supply consistent, DCGI-approved anti-tubercular products to franchise partners and distributors who need dependable stock and district-wise monopoly support.
What is Ethambutol?
Ethambutol is a first-line anti-tuberculosis agent that inhibits arabinosyl transferase and disrupts mycobacterial cell wall synthesis. It is used in combination regimens to help prevent the emergence of drug resistance. Learn more from the PubChem compound record.
Available Ethambutol Formulations
Our current Ethambutol portfolio spans 4 Ethambutol formulations available in the following forms: Tablets. Every batch is quality tested and released under WHO-GMP controls to ensure uniform quality across supply cycles.
Therapeutic Applications
Ethambutol is indicated for combination treatment of pulmonary and extrapulmonary tuberculosis. It is prescribed by pulmonologists, chest and TB physicians, and infectious disease specialists and is dispensed strictly on prescription under qualified medical supervision.
Why Ethambutol is a High-Potential Molecule for Distributors
As a core companion drug in first-line TB regimens, ethambutol carries dependable programme-linked volumes for anti-infective focused distributors.
Why Choose Cafoli Lifecare
Partners receive district-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, complete promotional inputs, and the backing of a network of 1000+ franchise partners across India. Our supply reliability and compliance-first approach help you build a durable Ethambutol franchise business.
References
- PubChem: Ethambutol
- MedlinePlus: Ethambutol
- PubMed: Ethambutol research
Our formulations of Ethambutol find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: